# A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV

> **NCT06564194** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Immorna Biotherapeutics, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)
- Infectious Disease

## Interventions

- **BIOLOGICAL:** JCXH-108
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06564194
- **Lead sponsor:** Immorna Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06564194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06564194, "A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT06564194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*